European Heart Journal· 2017Q1· Guideline
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
- 2,988citations
- Q1SCImago
- 2017year
Short summary
This focused update provides recommendations on dual antiplatelet therapy (DAPT) duration and drug choice for patients with coronary artery disease (CAD), considering new evidence on risks and benefits.
AI-generated from the title and abstract; the full text is not read.
Key points
- Provides updated recommendations for dual antiplatelet therapy (DAPT) in coronary artery disease (CAD).
- Addresses DAPT duration and drug choice based on current scientific evidence.
- Aims to balance the benefits of preventing thrombotic events with the risks of bleeding.
- Emphasizes the role of clinical judgment in applying guidelines to individual patient care.
AI-generated from the title and abstract; the full text is not read.
Abstract
The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
The authors' abstract, as published at the source. European Heart Journal, 2017 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Cardiology and Cardiovascular Medicine
Cardiology and Cardiovascular MedicineMedicine